During Tuesday’s Current trade, Shares of Kimberly Clark Corp (NYSE:KMB), lost -1.12% to $105.34.
Kimberly-Clark Corporation (KMB) will webcast its participation in the 2015 Barclays Global Consumer Staples Conference from 9:30 a.m. to 10:10 a.m. CDT on Wednesday, September 9. Tom Falk, Chairman and CEO, and Maria Henry, Senior Vice President and CFO, will make a presentation about the company’s strategies for growing its global consumer and professional businesses and will subsequently answer questions from conference attendees.
Kimberly-Clark Corporation, together with its auxiliaries, manufactures and markets personal care, consumer tissue, and K-C professional products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Kotex, U by Kotex, Intimus, Depend, Plenitud, Poise, and other brands.
Shares of Fluor Corporation (NEW) (NYSE:FLR), declined -2.54% to $44.47, during its current trading session.
Fluor Corporation (NEW) (FLR) declared that the U.S.-China Business Council (USCBC) has elected Fluor’s Chief Operating Officer, Peter Oosterveer, to its board. As a USCBC board member, Oosterveer will work to advance the commercial relationship between the two countries to support trade and investment opportunities.
Fluor Corporation, through its auxiliaries, provides engineering, procurement, construction, fabrication and modularization, commissioning and maintenance, and project administration services worldwide. The company operates in five segments: Oil & Gas, Industrial & Infrastructure, Government, Global Services, and Power. The Oil & Gas segment offers a range of design, engineering, procurement, construction, and project administration services to upstream oil and gas production, liquefied natural gas, downstream refining, offshore production, pipeline, chemicals, and petrochemicals industries. It also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies.
Exelixis, Inc. (NASDAQ:EXEL), during its Tuesday’s current trading session decreased -3.70% to $5.73.
Exelixis, Inc. (EXEL) declared the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, counting deep expertise in global financial operations and controls, planned planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. He formerly spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company’s divisions and regions. He joins Exelixis in advance of several potentially transformational milestones anticipated this year, counting top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization.
In this role, Mr. Senner will oversee the company’s global finance function, leveraging extensive experience gained earlier in his career. While at Gilead, he was accountable for controllership and operational financial planning and analysis, counting research and development, manufacturing, commercial operations, and tax and treasury planning. At Wyeth, he served in a variety of capacities, most notably as CFO of the company’s $10 billion U.S. pharmaceuticals business and the BioPharma Business Unit, a $5 billion global inflammation, oncology and hematology business.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising about 45 clinical trials, counting 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC).
Finally, Best Buy Co Inc (NYSE:BBY), decreased -1.96%, to $36.03.
Best Buy is proud to declare the nationwide launch of Geek Squad Academy. Successfully introduced to Canada as a pilot program earlier this year, the success of Geek Squad Academy is in its partnerships with local non-profit organizations and schools to teach youth aged 10-14 years about the latest technology in a fun, interactive environment.
While attending a Geek Squad Academy, students become ‘Junior Agents’ to get hands-on experience with some of the newest and coolest technology. This exposure to technology has become a fundamental resource for recently’s youth, as 70% of Canada’s top jobs require tech-based skills. Learning how to be innovative, creative, and adaptive to technology will assist to set students up for success.
To coincide with recently’s launch, Best Buy Canada has partnered with the Boys and Girls Club of Ottawa to host the first Geek Squad Academy in Canada . In subsequent months, Geek Squad Academy will be enlisting Junior Agents from across Canada , with camps planned for St. Albert , Brantford , and Winnipeg .
Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States and internationally. Its stores offer consumer electronics comprising primarily of television and home theaters; digital cameras and camcorders; DVD and Blu-ray players; portable electronics, such as MP3 devices, headphones and speakers, car stereo, navigation and satellite radio; and related accessories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
